High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring inETV6‐RUNX1‐positive acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring inETV6‐RUNX1‐positive acute lymphoblastic leukemia

Published:2019-04-29 Issue:8 Volume:66 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Hoffmann Jana¹,Krumbholz Manuela²,Gutiérrez Helia Pimentel¹,Fillies Marion¹,Szymansky Annabell¹,Bleckmann Kirsten³,zur Stadt Udo⁴,Köhler Rolf⁵,Kuiper Roland P.⁶,Horstmann Martin⁷⁸,Stackelberg Arend¹,Eckert Cornelia¹^ORCID,Metzler Markus²

Affiliation:

1. Pediatric Oncology/HematologyCharité – Universitätsmedizin Berlin Berlin Germany

2. Pediatric Oncology/HematologyUniversity Hospital Erlangen Erlangen Germany

3. Department of PediatricsUniversity of Schleswig‐Holstein Kiel Germany

4. Center for DiagnosticsUniversity Medical Center Hamburg‐Eppendorf Hamburg Germany

5. Institute of Human GeneticsUniversity of Heidelberg Heidelberg Germany

6. Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands

7. Research Institute Children's Cancer Center Hamburg Germany

8. Department of Pediatric Hematology and OncologyUniversity Medical Center Hamburg‐Eppendorf Hamburg Germany

Funder

Deutsche Kinderkrebsstiftung

José Carreras Leukämie-Stiftung

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.27780

Reference49 articles.

1. Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient;Schrappe M;Hematology Am Soc Hematol Educ Program,2012

2. Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group

3. Relapse in children with acute lymphoblastic leukaemia involving selection of a pre‐existing drug resistant sub‐clone;Choi S;Blood,2007

4. Very early/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment

5. Assessment of clonal stability of minimal residual disease targets between 1st and 2nd relapse of childhood precursor B‐cell acute lymphoblastic leukemia;Guggemos A;Haematologica,2003

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Approach for MRD Monitoring in Acute Lymphoblastic Leukemia;HemaSphere;2023-09-19

2. Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment;Scientific Reports;2023-09-13

3. Advanced Minimal Residual Disease Monitoring for Acute Lymphoblastic Leukemia with Multiplex Mediator Probe PCR;The Journal of Molecular Diagnostics;2022-01

4. Comparison of Two Quantitative PCR–Based Assays for Detection of Minimal Residual Disease in B-Precursor Acute Lymphoblastic Leukemia Harboring Three Major Fusion Transcripts;The Journal of Molecular Diagnostics;2021-10

5. Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all;British Journal of Haematology;2021-08